Introduction
Based on results from various large-scale clinical trials, hospital administration of intravenous thrombolysis is now the recognised method for treating acute myocardial infarction. A post hoc analysis of results from trials assessing hospital thrombolytic therapy suggests that early administration reduces infarct size and improves survival' Results from a number of trials studying prehospital vs hospital thrombolytic therapy for acute myocardial infarction provide compelling evidence that the former approach is feasible' 4 " 8 '. In the European Myocardial Infarction Project (EMIP), which represents one of these trials' 4 ', the results demonstrated a nonsignificant trend towards reduction of total 30-day mortality in favour of the pre-hospital group (13% reduction; />=008), and a significant 16% reduction in the incidence of cardiac mortality in favour of the pre-hospital group (V>=0-049). In addition, the EMIP findings showed that treating patients outside hospital resulted in a median time gain to treatment of almost 1 h, and that this early treatment is probably responsible for the reduction in mortality. However, the expected benefit from treatment is not constant over time, so that early treatment offers more potential benefit than later treatment 12 "". EMIP evaluated the thrombolytic agent anistreplase, which is particularly well suited to the prehospital setting, since it can be administered as a 5-min intravenous bolus. However, other thrombolytic agents such as streptokinase, urokinase, and recombinant tissue plasmin activator have been successfully used in this setting 16 " 101 .
The purpose of the present study was to analyse the EMIP data to examine the various components of the delay from onset of symptoms to treatment (both pre-hospital and in-hospital) and to identify the characteristics of patients who sought treatment early.
Methods

Patients and treatment
Between October 1988 and January 1992, 5469 patients were enrolled in the EMIP trial by 198 mobile emergency units in 15 European countries and Canada. Patients were included in the trial if no more than 6 h had elapsed since symptom onset. (Consult the EMIP primary outcome report for further information' 4 '.) They received a 5-min bolus injection immediately (either 30 IU of anistreplase or placebo) followed by a second 5-min bolus injection on arrival at hospital (either placebo or 30 IU of anistreplase). All patients received two injections, thus maintaining the doubleblind design of the study.
Data collection and quality control
Baseline variables were noted on a pre-hospital study form completed in the ambulance, and a hospital study form was completed by the emergency department and ward staff during the hospitalization period. The study forms were sent to the EMIP Coordinating Centre at regular intervals for quality control and archival purposes. Confirmation and/or corrections were requested when erroneous or questionable data were found.
Outcomes
For analysis of the delays, the following times were noted on the study forms: onset of symptoms, call for ambulance, ambulance arrival, pre-hospital injection given, hospital admission, and hospital injection given. Confirmation or not of the diagnosis of myocardial infarction was obtained before discharge. Ten baseline variables were used in the correlation analyses: acute pulmonary oedema, age, cardioversion after inclusion, gender, pain in the 24 h prior to inclusion, pain still present, previous angina, previous myocardial infarction, shock, and ventricular fibrillation.
Statistical methods
Univariate analysis of delays between onset of symptoms and call for an ambulance, onset of symptoms and the pre-hospital injection, arrival of the ambulance and arrival at hospital, and the pre-hospital and hospital injections were performed on subgroups of patients defined by baseline characteristics (Wilcoxon rank sum test). Linear regression (using a generalized linear model) was used to identify which baseline characteristics correlated with a longer or shorter delay between onset of symptoms and pre-hospital injection, between the two injections, and between hospital arrival and hospital injection.
Results
The characteristics of the patients in the two groups were similar, and those for the study population as a Prior myocardial infarction (n %) Prior angina pectoris (n %) Prior atherosclerotic diseases (n %) Before randomization Ventricular fibrillation (n %) Shock (n %) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Heart rate (beats . min ~ ') Stratification Elevated ST (n %)
Final diagnosis Myocardial infarction (n %) Probable myocardial infarction (n %)t Acute coronary syndrome (n %)
Compliance Both injections (n %) Pre-hospital injection only (n %) Hospital injection only (n %) No study injections (n %) Incomplete information (n %) Death before hospital injection (n %) -8) 88 (1-6) 390( 7 1) 21 (0-4)
"(mean ± SD). tThese patients died before final diagnosis could be made whole are summarized in Table 1 . The median delays recorded for all patients are shown in Fig. 1 , and the details for each country are given in Table 2 . Patients receiving pre-hospital treatment were treated 55 min (median value) earlier than patients receiving in-hospital treatment.
Relationships between baseline variables and various time delays
The results from the univariate analysis are summarized in Table 3 . With one exception (patients with previous angina), the delay between symptom onset to call and the delay between symptom onset to first injection (first two columns, Table 3 ) increased or decreased similarly for each patient characteristic. The results from the linear regression analyses for the delay between symptom onset and call showed that patients over 65 years old and those who had pain within the previous 24 h were significantly more likely to wait longer before calling for an ambulance (/ > =00001 for both). Women, and those with previous pulmonary oedema were also likely to wait longer (P=0-003 and / ) =002, respectively), whereas those with ventricular fibrillation, previous myocardial infarction and those in shock were significantly more likely to have a shorter delay (/>=0-02, 003, and 00001, respectively). The results from linear regression analyses for the delay between the pre-hospital and the hospital injection showed that patients over 65 years old, those with previous myocardial infarction, and those experiencing shock had a significantly longer delay between the two injections (/ ) =0002, 004, and 00001, respectively), and those who had previously suffered from angina pectoris were likely to have a shorter delay between the two injections (/ ) =0048). No other variable tested was found to be significantly correlated with either delay. Patients with a longer delay between onset of symptoms and pre-hospital injection had a non-significantly shorter delay between the two injections.
Discussion
Our post hoc analysis of patient characteristics associated with various time delays to thrombolytic therapy differs from most previous studies examining these phenomena. While others' 10 ' concentrated on hospitalbased delays, we correlated patient baseline characteristics with pre-hospital as well as hospital delays. Thus, comparisons between our analyses and those of others are limited.
Maynard et a/.' 12 ' examined the relationship between patient characteristics and delay between onset of symptoms and treatment in a post hoc analysis of patients enrolled in three different thrombolytic therapy trials. Their conclusions were that patients arriving earlier at hospital (within 2 h of symptom onset) were significantly younger than those who arrived later (55-6 vs 58-2 years), and these early patients were significantly more likely to be hypotensive and to have cardiogenic shock. They observed no significant differences in terms of sex or previous myocardial infarction. Some of our findings are consistent with Maynard's group (younger patients tended to call the ambulance earlier), while other results from our analyses indicate a clear difference in terms of gender and previous myocardial infarction (men and those who had a previous myocardial infarction tended to call sooner).
In correlating patient characteristics with the length of the components of delays to thrombolytic therapy, we have attempted to identify factors that could feasibly be altered, and which thus could reduce the time to treatment. Although age, gender and previous myocardial infarction were not associated with any overall delay between calling for help and ambulance arrival (third column, Table 3 ), older individuals, women, and those who had had a previous myocardial infarction or who experienced pain within the previous 24 h waited longer to call the ambulance. These findings suggest that the elderly, females in particular, and those at risk for cardiovascular disease could be targeted for Eur Heart J. Vol. 18, February 1997 Delays in thrombolytic treatment in patients with suspected AMI 251 Wilcoxon rank sum test used to determine significance levels (*/><005, **/><0005; ***/ > <00005).
interventions aimed at teaching them to recognise the symptoms of acute myocardial infarction and the importance of obtaining prompt treatment. Our observation, that patients who had had a previous myocardial infarction called for help sooner than patients who had never experienced an myocardial infarction supports this approach, since it is likely that previous familiarity with symptoms of a heart attack would prompt this group to call sooner. An equally important approach would be to make physicians aware of this association between delayed called for help and age, gender and previous myocardial infarction. It is perhaps not surprising that for those patients experiencing complications such as shock and cardioversion, the length between the two injections, which reflects an extended transportation delay due to the need for stabilization, was significantly longer (5-10 min). Interventions aimed at shortening this interval may not be feasible, given that medical complications frequently require additional and time-consuming measures. For these patients, pre-hospital therapy could provide more expeditious treatment. A standard protocol aimed at efficient and prudent triaging. diagnosis, and treatment should be operational for all mobile emergency unit personnel and, if pre-hospital therapy is not feasible, for hospital staff as well.
The results of our analyses must be considered in the context of the EMIP trial conditions. Our findings apply only to situations in which patients with suspected acute myocardial infarction are cared for by mobile emergency units, which, in the EMIP trial, all had a physician on board. In addition, EMIP patients were selected according to pre-specified criteria, as is the case with any targeted clinical trial population. Thus, patients in this trial may not represent all patients with suspected acute myocardial infarction, although they are similar to patients admitted directly to hospital'" 1 . Despite these limitations, analysis of the different components of the delay between symptom onset and treatment provides some insights into where efforts could be made to reduce the overall time to treatment.
Using the data in the EMIP trial it is tempting to compare the delays between countries, but this must be done with caution since in many countries there were only a few trial centres, and therefore the differences may simply reflect differences in the type of setting (rural, urban, etc.) rather than real differences between the countries. For example in Denmark two Copenhagen centres enrolled 31 patients, and the single Swiss centre enrolled only seven patients, compared with the 111 centres in France that enrolled 3046 patients. Thus, although the delays in Northern Ireland and France, whose systems are similar, were found to be comparable (Table 2) , the median overall delay from the onset of symptoms to the hospital injection varied from 93 min in Denmark (Copenhagen) to 255 min in Spain (Barcelona). In Spain this delay is mainly due to the length of the delay (120 min) between the onset of symptoms and the call for the ambulance.
In conclusion, our post hoc analysis of data from EMIP indicates that the various components of the time delay from symptom onset to treatment for patients with suspected myocardial infarction are influenced by nonmodifiable and modifiable factors. Although it would be difficult to shorten the transportation time (due to the need for patient stabilization as well as factors such as traffic conditions and driving distance), efforts to reduce the time interval between symptom onset and calling the ambulance are feasible and should, therefore, be undertaken.
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